Skip to Content

News Series Conferences Insights FeaturesMORE

FORTUNE LIVE MEDIA

FORTUNE CONNECT

FORTUNE EDUCATION

FORTUNE RECOMMENDS

SIGN IN

Loading Video...

Behind 23andMe’s Venture into Drug Development

December 04, 2015 22:32 PM UTC
- Updated November 05, 2019 13:45 PM UTC

CEO Anne Wojcicki discusses the company’s plan.

Sections

Tags

23andme23andme ceo23andme drug developmentanne wojcickiceo anne wojcickifortune liveyoutube

Rankings

40 Under 40
100 Best Companies
Fortune 500
Global 500
Most Powerful Women
World’s Greatest Leaders
World’s Most Admired Companies
See All Rankings

Sections

Automotive
Careers
Design
Executive Travel
The Ledger
Venture
Finance
Energy and Environment
Health
International
Leadership
Luxury
Retail
Sports
Technology
Commentary

Customer Support

Digital Registration FAQ
Customer Service
EU Customer Service
US Privacy Policy

Commercial Services

FORTUNE Knowledge Group
FORTUNE Branded Content
Fortune Data Store
Fortune Conferences
Advertising

About Us

About Us
Online Behavioral Advertising Notice
FORTUNE Website and Application Terms and Conditions of Use

© 2023 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information | Ad Choices
Fortune may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions. | EU Data Subject Requests